Full Press Release Details
CORAL GABLES, Fla., Oct. 21, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will be making a presentation on Tuesday, October 25th at 11:00 a.m. PST at the 10th Annual BIO Investor Forum. The forum will be held on October 25th through October 26th at the Palace Hotel in San Francisco, California. Hosted by the Biotechnology Industry Organization, the 10th Annual BIO Investor Forum is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on leading public and venture-stage growth companies.
Catalyst will present a Corporate Overview, including its development plans for CPP-109 and CPP-115. Further, the Company reported that its presentation materials from the forum will be posted on October 25th on the Company's website, www.catalystpharma.com, under "Events and Presentations."
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin), for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and for other selected central nervous disease indications. CPP-115 has been granted orphan-drug designation for the treatment of infantile spasms by the FDA. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to www.catalystpharma.com.